Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy

Transplantation

Volumn 71, Issue 7, 2001, Pages 910-913

  Singh, N ^a   Paterson, D L ^a   Gayowski, T ^a   Wagener, M M ^a   Marino, I R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL RATE;

EID: 0035870741     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200104150-00016     Document Type: Article

References (28)

1. Bacterial and fungal infections after liver transplantation: An analysis of 284 patients
2. Risk factors for systemic fungal infections in liver transplant recipients
3. Invasive fungal infections in liver transplant recipients receiving tacrolimus as primary immunosuppressive agent
4. Risk factors for invasive fungal infections complicating orthotopic liver transplantation
5. Clinical spectrum of fungal infections after orthotopic liver transplantation
6. Invasive aspergillosis in transplant recipients
7. Factors associated with invasive lung aspergillosis and significance of positive cultures after liver transplantation
8. 10 Year review of invasive aspergillosis detected at necropsy
9. Antifungal prophylaxis in organ transplant recipients: Seeking clarity amidst controversy
10. Human herpesvirus-6 in liver transplant recipients: Role in pathogenesis of fungal infections, neurologic complications, and impact on outcome
11. Orthotopic liver transplantation in high risk patients: Risk factors associated with mortality and infectious morbidity
12. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil
13. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients, a randomized trial
14. Infections after liver transplantation, an analysis of 101 consecutive cases
15. Invasive aspergillosis in liver transplant recipients in the 1990s
16. Systemic mycoses during prophylactical use of liposomal amphotericin B (AmBisome) after liver transplantation
17. Itraconazole, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses
18. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies; a randomized, placebo-controlled, double-blind, multicenter trail
19. Efficacy of itraconazole prophylaxis against systemic fungal infection in liver transplant recipients
20. Invasive aspergillosis in liver transplant recipients: Association with candidemia, consumption coagulopathy, and failure of prophylaxis with low-dose amphotericin B
21. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
22. Invasive aspergillosis in liver transplant recipients: Comparison of outcome with amphotericin B LIPID complex and conventional amphotericin B therapy
23. Liposomal amphotericin B and amphotericin B-Deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells
24. Fungal infection prophylaxis in high-risk liver transplant recipients
25. Continuous venovenous hemorenal replacement therapy treatment in critically ill patients liver transplantation
26. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection after liver transplantation
27. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial
28. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients